Screener
Aurinia Pharmaceuticals AUPH EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Aurinia Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's EBITDA margin?
- Aurinia Pharmaceuticals (AUPH) reported EBITDA margin of 54.6% in Q2 2026.
- How has Aurinia Pharmaceuticals's EBITDA margin changed year-over-year?
- Aurinia Pharmaceuticals's EBITDA margin increased by 98.7% year-over-year, from 27.5% to 54.6%.
- What is the long-term trend for Aurinia Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's EBITDA margin has grown at a -26.5% compound annual growth rate (CAGR), from -205.4% to 43.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Aurinia Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude